Tirzepatide and health‐related quality of life in adults with obesity or overweight: Results from the SURMOUNT ‐3 phase 3 randomized trial

Ähnliche Einträge

• Improved health‐related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT ‐5 trial
  von: Alpana P. Shukla, et al.
  Veröffentlicht: (2025)
• Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight
  von: Michelle Look, et al.
  Veröffentlicht: (2025)
• Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT ‐1 to ‐4 trials
  von: Domenica M. Rubino, et al.
  Veröffentlicht: (2025)
• Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison
  von: Emily R. Hankosky, et al.
  Veröffentlicht: (2025)
• Predicting 10‐year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT ‐ CN trial
  von: Lin Zhao, et al.
  Veröffentlicht: (2025)